2026-10-12T13:54:10Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/88062024-03-13T01:05:23Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220

00925njm 22002777a 4500 dc Santos García, Diego author Deus-Fonticoba, Teresa de author Cores Bartolomé, Carlos author Muñoz, Guillermo author Paz González, José Manuel author Martínez Miró, Cristina author Suárez Castro, Ester author Jesús, Silvia author Aguilar, Miquel author Pastor, Pau author Planellás, Lluis L. author Cosgaya, Marina author García Caldentey, Juan author Caballol, Núria author Legarda, Inés author Hernández Vara, Jorge author Cabo López, Iria author López Manzanares, Luis author González Aramburu, Isabel author López Manzanares, Luis author González Aramburu, Isabel author Ávila Rivera, María A. author Catalán, María José author Nogueira, Víctor author Puente, Víctor author Ruíz de Arcos, María author Borrue, Carmen author Solano Vila, Berta author Álvarez Saúco, María author Vela Desojo, Lydia author Escalante Arroyo, Sonia author Cubo Delgado, Esther author Carrillo Padilla, Francisco author Martínez Castrillo, Juan Carlos author Sánchez Alonso, Pilar author Alonso Losada, María Gema author López Ariztegui, Nuria author Gastón, Itziar author Clavero Ibarra, Pedro author Kulisevsky Bojarsky, Jaume author Blázquez Estrada, Marta author Seijo, Manuel author Ruíz Martínez, Javier author Valero, Caridad author Kurtis, Mónica M. author Fabregues, Oriol de author González Ardura, Jessica author Ordás Bandera, Carlos Manuel author López Díaz, Luis M. author McAfee, Darrian author Martínez Martín, Pablo author Mir, Pablo author COPPADIS Study Group author 2021-12 Quality of life (QOL) plays an important role in independent living in Parkinson’s disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson’s disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829–0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422–12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053–1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027–1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer–Lemeshow test, p = 0.665; R 2 = 0.655). An increase in ≥5 and ≥10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663–17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975–22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients. http://hdl.handle.net/10259/8806 10.1038/s41531-021-00256-w 2373-8057 Predictors of clinically significant quality of life impairment in Parkinson’s disease